fda semaglutide warning september 2025 8, 2025: launches an import alert listing safe GLP-1 manufacturers – Partnership for Safe Medicines FDA sends letter to Novo
Description
Clear answers matter before anyone commits to a long-term weight-loss plan
Kidney problems: Individuals with severe kidney issues may not be suitable candidates
The data were extracted by two authors (SG and BS), and eligibility based on the predetermined inclusion criteria was assessed by both
Some patients may also experience mild side effects, such as nausea or digestive discomfort, which can temporarily affect their appetite and food intake
Customized Dosing and Medication Selection Everyones body reacts differently to medications, so finding the right fit is essential
